| Year |
Citation |
Score |
| 2021 |
Cohen-Cymberknoh M, Ben Meir E, Gartner S, Reiter J, Spangenberg A, Garriga L, Eisenstadt I, Israeli T, Tsabari R, Shoseyov D, Gileles-Hillel A, Breuer O, Simanovsky N, Kerem E. How abnormal is the normal? Clinical characteristics of CF patients with normal FEV. Pediatric Pulmonology. PMID 33704929 DOI: 10.1002/ppul.25371 |
0.308 |
|
| 2020 |
de Benedictis FM, Kerem E, Chang AB, Colin AA, Zar HJ, Bush A. Complicated pneumonia in children. Lancet (London, England). 396: 786-798. PMID 32919518 DOI: 10.1016/S0140-6736(20)31550-6 |
0.33 |
|
| 2020 |
Cohen-Cymberknoh M, Gindi Reiss B, Reiter J, Lechtzin N, Melo J, Pérez G, Blau H, Mussaffi H, Levine H, Bentur L, Gur M, Livnat G, Perez Miranda J, Polverino E, Blasi F, ... ... Kerem E, et al. Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 32917549 DOI: 10.1016/J.Jcf.2020.09.002 |
0.331 |
|
| 2020 |
Munck A, Kerem E, Ellemunter H, Campbell D, Wang LT, Ahluwalia N, Owen CA, Wainwright C. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 32546431 DOI: 10.1016/J.Jcf.2020.04.015 |
0.318 |
|
| 2020 |
De Boeck K, Lee T, Amaral M, Drevinek P, Elborn JS, Fajac I, Kerem E, Davies JC. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 19: 688-695. PMID 32527602 DOI: 10.1016/J.Jcf.2020.05.012 |
0.38 |
|
| 2020 |
Konstan MW, VanDevanter DR, Rowe SM, Wilschanski M, Kerem E, Sermet-Gaudelus I, DiMango E, Melotti P, McIntosh J, De Boeck K. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 31983658 DOI: 10.1016/J.Jcf.2020.01.007 |
0.4 |
|
| 2019 |
Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, ... ... Kerem E, et al. The future of cystic fibrosis care: a global perspective. The Lancet. Respiratory Medicine. PMID 31570318 DOI: 10.1016/S2213-2600(19)30337-6 |
0.391 |
|
| 2019 |
Amaral MD, Boeck Kd, Amaral M, Davies JC, Drevinek P, Elborn S, Kerem E, Lee T. Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations. Journal of Cystic Fibrosis. 18: 685-692. PMID 31326274 DOI: 10.1016/J.Jcf.2019.06.010 |
0.361 |
|
| 2019 |
Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T, Amaral MD, de Boeck K, Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 31303382 DOI: 10.1016/J.Jcf.2019.06.011 |
0.338 |
|
| 2019 |
Cohen-Cymberknoh M, Atia O, Gileles-Hillel A, Kerem E, Reiter J. Sleep disorders in patients with primary ciliary dyskinesia, cystic fibrosis with and without pancreatic insufficiency. Respiratory Medicine. 151: 96-101. PMID 31047123 DOI: 10.1016/J.Rmed.2019.03.022 |
0.399 |
|
| 2019 |
Cohen-Cymberknoh M, Atia O, Gileles-Hillel A, Kerem E, Reiter J. ePS2.02 Comparison of sleep disorders between patients with primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency Journal of Cystic Fibrosis. 18: S42. DOI: 10.1016/S1569-1993(19)30250-4 |
0.307 |
|
| 2019 |
Reiter J, Gileles-Hillel A, Cohen-Cymberknoh M, Kerem E, Forno E. ePS2.01 Polysomnographic findings in cystic fibrosis: a meta-analysis Journal of Cystic Fibrosis. 18: S42. DOI: 10.1016/S1569-1993(19)30249-8 |
0.354 |
|
| 2018 |
Bush A, Griese M, Seidl E, Kerem E, Reu S, Nicholson AG. Early onset children's interstitial lung diseases: Discrete entities or manifestations of pulmonary dysmaturity? Paediatric Respiratory Reviews. PMID 30552058 DOI: 10.1016/J.Prrv.2018.09.004 |
0.35 |
|
| 2018 |
Abu-Fraiha Y, Elyashar-Earon H, Shoseyov D, Cohen-Cymberknoh M, Armoni S, Kerem E, Wilschanski M. Increasing Vitamin D Serum Levels Is Associated with Reduced Pulmonary Exacerbations in Patients with Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition. PMID 30095576 DOI: 10.1097/Mpg.0000000000002126 |
0.346 |
|
| 2018 |
Shamriz O, Shadur B, NaserEddin A, Zaidman I, Simanovsky N, Elpeleg O, Kerem E, Reiter J, Stepensky P. Respiratory manifestations in LPS-responsive beige-like anchor (LRBA) protein-deficient patients. European Journal of Pediatrics. PMID 29777306 DOI: 10.1007/S00431-018-3171-5 |
0.358 |
|
| 2018 |
Ben-Meir E, Eisenstadt I, Israeli T, Tsabari R, Breuer O, Reiter J, Gileles-Hillel A, Shoseyov D, Kerem E, Cohen-Cymberknoh M. EPS6.04 Correlation between six-minutes-walk-test and cystic fibrosis disease severity Journal of Cystic Fibrosis. 17: S49. DOI: 10.1016/S1569-1993(18)30272-8 |
0.34 |
|
| 2017 |
Cohen-Cymberknoh M, Tanny T, Breuer O, Blau H, Mussaffi H, Kadosh D, Gartner S, Salinas A, Bentur L, Nir V, Gur M, Reiter J, Shoseyov D, Kerem E, Berger I. Attention deficit hyperactivity disorder symptoms in patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 29269187 DOI: 10.1016/J.Jcf.2017.11.020 |
0.341 |
|
| 2017 |
Guen VJ, Edvardson S, Fraenkel ND, Fattal-Valevski A, Jalas C, Anteby I, Shaag A, Dor T, Gillis D, Kerem E, Lees JA, Colas P, Elpeleg O. A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness. American Journal of Medical Genetics. Part A. PMID 29130579 DOI: 10.1002/Ajmg.A.38506 |
0.313 |
|
| 2017 |
Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. The New England Journal of Medicine. PMID 29099333 DOI: 10.1056/Nejmoa1709847 |
0.392 |
|
| 2017 |
Cohen-Cymberknoh M, Weigert N, Gileles-Hillel A, Breuer O, Simanovsky N, Boon M, De Boeck K, Barbato A, Snijders D, Collura M, Pradal U, Blau H, Mussaffi H, Price M, Bentur L, ... ... Kerem E, et al. Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia. Respiratory Medicine. 131: 241-246. PMID 28947038 DOI: 10.1016/J.Rmed.2017.08.028 |
0.364 |
|
| 2017 |
Dagan A, Cohen-Cymberknoh M, Shteinberg M, Levine H, Vilozni D, Bezalel Y, Bar Aluma BE, Sarouk I, Ashkenazi M, Lavie M, Tsabari R, Blau H, Kerem E, Bentur L, Efrati O, et al. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience. Respiratory Medicine. 131: 225-228. PMID 28947035 DOI: 10.1016/J.Rmed.2017.08.026 |
0.335 |
|
| 2017 |
Kerem E. Cystic fibrosis: Priorities and progress for future therapies. Paediatric Respiratory Reviews. PMID 28697970 DOI: 10.1016/J.Prrv.2017.06.004 |
0.382 |
|
| 2017 |
Behar DM, Inbar O, Shteinberg M, Gur M, Mussaffi H, Shoseyov D, Ashkenazi M, Alkrinawi S, Bormans C, Hakim F, Mei-Zahav M, Cohen-Cymberknoh M, Dagan A, Prais D, Sarouk I, ... ... Kerem E, et al. Nationwide genetic analysis for molecularly unresolved cystic fibrosis patients in a multiethnic society: implications for preconception carrier screening. Molecular Genetics & Genomic Medicine. 5: 223-236. PMID 28546993 DOI: 10.1002/Mgg3.278 |
0.389 |
|
| 2017 |
Breuer O, Daum H, Cohen-Cymberknoh M, Unger S, Shoseyov D, Stepensky P, Keller B, Warnatz K, Kerem E. Autosomal dominant gain of function STAT1 mutation and severe bronchiectasis. Respiratory Medicine. 126: 39-45. PMID 28427548 DOI: 10.1016/J.Rmed.2017.03.018 |
0.43 |
|
| 2017 |
Tanny T, Breuer O, Blau H, Kadosh D, Mussaffi H, Gartner S, Salinas A, Bentur L, Nir V, Gur M, Shoseyov D, Kerem E, Berger I, Cohen-Cymberknoh M. EPS2.6 Prevalence and characteristics of attention deficit hyperactivity disorder in patients with cystic fibrosis Journal of Cystic Fibrosis. 16: S40. DOI: 10.1016/S1569-1993(17)30289-8 |
0.31 |
|
| 2016 |
Wilschanski M, Yaakov Y, Omari I, Zaman M, Martin CR, Cohen-Cymberknoh M, Shoseyov D, Kerem E, Dasilva D, Sheth S, Uluer A, OʼSullivan B, Freedman S. Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR function. Journal of Pediatric Gastroenterology and Nutrition. PMID 27496797 DOI: 10.1097/Mpg.0000000000001366 |
0.391 |
|
| 2016 |
Reiter J, Szafranski P, Breuer O, Perles Z, Dagan T, Stankiewicz P, Kerem E. Variable phenotypic presentation of a novel FOXF1 missense mutation in a single family. Pediatric Pulmonology. PMID 27145217 DOI: 10.1002/Ppul.23425 |
0.326 |
|
| 2016 |
Cohen-Cymberknoh M, Gilead N, Gartner S, Rovira S, Blau H, Mussaffi H, Rivlin J, Gur M, Shteinberg M, Bentur L, Livnat G, Aviram M, Picard E, Tenenbaum A, Armoni S, ... ... Kerem E, et al. Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 27143583 DOI: 10.1016/J.Jcf.2016.04.006 |
0.408 |
|
| 2016 |
Cohen-Cymberknoh M, Shoseyov D, Breuer O, Shamali M, Wilschanski M, Kerem E. Treatment of cystic fibrosis in low-income countries. The Lancet. Respiratory Medicine. 4: 91-2. PMID 26868623 DOI: 10.1016/S2213-2600(15)00507-X |
0.306 |
|
| 2016 |
Breuer O, Shteyer E, Wilschanski M, Perles Z, Cohen-Cymberknoh M, Kerem E, Shoseyov D. Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease. Chest. 149: e35-8. PMID 26867851 DOI: 10.1016/J.Chest.2015.10.040 |
0.401 |
|
| 2016 |
Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 26852040 DOI: 10.1016/J.Jcf.2015.12.004 |
0.389 |
|
| 2016 |
Levine H, Cohen-Cymberknoh M, Klein N, Hoshen M, Mussaffi H, Stafler P, Breuer O, Kerem E, Blau H. Reversible airway obstruction in cystic fibrosis: Common, but not associated with characteristics of asthma. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 26826913 DOI: 10.1016/J.Jcf.2016.01.003 |
0.376 |
|
| 2016 |
Sermet-Gaudelus I, Tiddens H, Malfroot A, Heijerman H, Kerem E, Hjelte L, Sun Y, McIntosh J, Davies J, Boeck Cd. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function European Respiratory Journal. 48. DOI: 10.1183/13993003.Congress-2016.Pa4869 |
0.398 |
|
| 2016 |
Kerem E, Sermet-Gaudelus I, Hjelte L, Boeck KD. 264 Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study Journal of Cystic Fibrosis. 15: S118-S119. DOI: 10.1016/S1569-1993(16)30502-1 |
0.396 |
|
| 2016 |
Mei-Zahav M, Mussaffi H, Efrati O, Blau H, Livnat G, Bentur L, Aviram M, Gur M, Kerem E. 256 Improved outcome in cystic fibrosis – results of the Israeli CF Patient Registry 2005–2013 Journal of Cystic Fibrosis. 15: S117. DOI: 10.1016/S1569-1993(16)30495-7 |
0.38 |
|
| 2016 |
Steg O, Shteyer E, Simanovsky N, Armoni S, Kerem E, Kelly D, Stewart L, Wilschanski M. WS17.1 Validation of a new ultrasonographic protocol for early diagnosis of cystic fibrosis liver disease (CFLD) Journal of Cystic Fibrosis. 15: S28. DOI: 10.1016/S1569-1993(16)30157-6 |
0.312 |
|
| 2016 |
Pugatsch T, Cohen-Cymberknoh M, Elyashar-Earon H, Eisenstadt I, Wilschanski M, Breuer O, Kurz S, Palmor S, Armoni S, Kerem E. WS16.5 Website based educational program on cystic fibrosis (CF) for community physicians Journal of Cystic Fibrosis. 15: S27. DOI: 10.1016/S1569-1993(16)30155-2 |
0.305 |
|
| 2016 |
Davies J, Tiddens H, Malfroot A, Heijerman H, Kerem E, Hjelte L, Sun J, Mcintosh J, Sermet-Gaudelus I, Boeck KD. WS13.1.1 Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range Journal of Cystic Fibrosis. 15: S21. DOI: 10.1016/S1569-1993(16)30133-3 |
0.388 |
|
| 2016 |
De Boeck K, Heijerman H, Davies J, Sermet-Gaudelus I, Hjelte L, Kerem E, Sun J, Mcintosh J, Malfroot A, Tiddens H. WS13.1 Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin Journal of Cystic Fibrosis. 15: S20-S21. DOI: 10.1016/S1569-1993(16)30132-1 |
0.397 |
|
| 2015 |
Pugatsch T, Shoseyov D, Cohen-Cymberknoh M, Hayut B, Armoni S, Griese M, Kerem E. Adherence pattern to study drugs in clinical trials by patients with cystic fibrosis. Pediatric Pulmonology. PMID 26583331 DOI: 10.1002/Ppul.23344 |
0.34 |
|
| 2015 |
Tsabari R, Elyashar HI, Cymberknowh MC, Breuer O, Armoni S, Livnat G, Kerem E, Zangen DH. CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 26547591 DOI: 10.1016/J.Jcf.2015.10.012 |
0.317 |
|
| 2015 |
Gileles-Hillel A, Shoseyov D, Polacheck I, Korem M, Kerem E, Cohen-Cymberknoh M. Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis. Pediatric Pulmonology. 50: 1082-9. PMID 26383963 DOI: 10.1002/Ppul.23302 |
0.395 |
|
| 2015 |
Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 14: 507-14. PMID 25592656 DOI: 10.1016/J.Jcf.2014.12.013 |
0.346 |
|
| 2015 |
Auerbach A, Kerem E, Assous MV, Picard E, Bar-Meir M. Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 14: 347-52. PMID 25308183 DOI: 10.1016/J.Jcf.2014.09.011 |
0.381 |
|
| 2015 |
Cohen-Cymberknoh M, Tanny T, Blau H, Kadosh D, Mussaffi H, Nir V, Bentur L, Shoseyov D, Kerem E, Berger I. 300 Prevalence and characteristics of attention deficit hyperactivity disorder (ADHD) in patients with cystic fibrosis (CF) Journal of Cystic Fibrosis. 14: S134. DOI: 10.1016/S1569-1993(15)30474-4 |
0.36 |
|
| 2015 |
Cohen-Cymberknoh M, Gilead N, Gartner S, Simanovski N, Canino E, Carreño J, Blau H, Mussaffi H, Gur M, Rivlin J, Bentur L, Aviram M, Picard E, Hiller N, Armoni S, ... ... Kerem E, et al. ePS06.7 Factors associated with failure to eradicate first or newly acquired Pseudomonas aeruginosa in patients with CF Journal of Cystic Fibrosis. 14: S54. DOI: 10.1016/S1569-1993(15)30175-2 |
0.373 |
|
| 2015 |
Cohen-Cymberknoh M, Bar G, Yaakov Y, Cohen M, Shoseyov D, Kerem E, Wilschanski M. WS20.3 Acquired CFTR dysfunction in patients with primary ciliary dyskinesia (PCD)? Journal of Cystic Fibrosis. 14: S37. DOI: 10.1016/S1569-1993(15)30118-1 |
0.404 |
|
| 2015 |
Abu-Fraiha Y, Elyashar-Earon H, Shoseyov D, Cohen-Cymberknoh M, Armoni S, Kerem E, Wilschanski M. WS04.5 Vitamin D influence on respiratory exacerbations and hospitalizations in cystic fibrosis patients Journal of Cystic Fibrosis. 14: S8. DOI: 10.1016/S1569-1993(15)30025-4 |
0.316 |
|
| 2014 |
Breuer O, Cohen-Cymberknoh M, Armoni S, Kerem E, Shoseyov D. Continuous intravenous β-lactam antibiotics in cystic fibrosis patients with severe drug hypersensitivity. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 113: 229-30. PMID 24934107 DOI: 10.1016/J.Anai.2014.05.014 |
0.324 |
|
| 2014 |
Kerem E, Webb AK. European Cystic Fibrosis Society Standards of Care: a road map to improve CF outcome. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 13: 357-8. PMID 24880531 DOI: 10.1016/J.Jcf.2014.05.003 |
0.309 |
|
| 2014 |
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine. 2: 539-47. PMID 24836205 DOI: 10.1016/S2213-2600(14)70100-6 |
0.376 |
|
| 2014 |
Peled O, Kalamaro V, Kerem E, Shoseyov D, Blau H, Efrati O, Block C. Contamination of hypertonic saline solutions in use by cystic fibrosis patients in Israel. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 13: 550-6. PMID 24484849 DOI: 10.1016/J.Jcf.2014.01.001 |
0.322 |
|
| 2014 |
Cohen-Cymberknoh M, Simanovsky N, Hiller N, Gileles Hillel A, Shoseyov D, Kerem E. Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency. Chest. 145: 738-44. PMID 24091606 DOI: 10.1378/Chest.13-1162 |
0.437 |
|
| 2014 |
Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. The European Respiratory Journal. 43: 125-33. PMID 23598952 DOI: 10.1183/09031936.00166412 |
0.418 |
|
| 2014 |
Breuer O, Cohen-Cymberknoh M, Armoni S, Kerem E, Shoseyov D. 222 Successful administration of continuous intravenous β-lactam therapy for allergic CF patients failing standard antibiotic desensitization Journal of Cystic Fibrosis. 13: S103. DOI: 10.1016/S1569-1993(14)60357-X |
0.325 |
|
| 2014 |
Cohen-Cymberknoh M, Gilead N, Shoseyov D, Breuer O, Blau H, Muzzafi H, Gur M, Rivlin J, Picard E, Armoni S, Aviram M, Bentur L, Kerem E. 147 Causes of failure to eradicate Pseudomonas aeruginosa in patients with CF Journal of Cystic Fibrosis. 13: S84. DOI: 10.1016/S1569-1993(14)60283-6 |
0.367 |
|
| 2014 |
Kerem E, Wilschanski M, Sermet-Gaudelus I, De Boeck K, Accurso F, Konstan M, Rowe S, Elfring G, Spiegel R, Peltz S, Barth J, Ajayi T. 94 The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis Journal of Cystic Fibrosis. 13: S70. DOI: 10.1016/S1569-1993(14)60230-7 |
0.391 |
|
| 2013 |
Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 68: 1157-62. PMID 23704228 DOI: 10.1136/Thoraxjnl-2013-203204 |
0.368 |
|
| 2013 |
Negari SB, Aouizerat T, Tenenbaum A, Cohen-Cymberknoh M, Shoseyov D, Kerem E, Saada A. Mitochondrial OXPHOS function is unaffected by chronic azithromycin treatment. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 12: 682-7. PMID 23680642 DOI: 10.1016/J.Jcf.2013.04.006 |
0.353 |
|
| 2013 |
Horani A, Ferkol TW, Shoseyov D, Wasserman MG, Oren YS, Kerem B, Amirav I, Cohen-Cymberknoh M, Dutcher SK, Brody SL, Elpeleg O, Kerem E. LRRC6 mutation causes primary ciliary dyskinesia with dynein arm defects. Plos One. 8: e59436. PMID 23527195 DOI: 10.1371/Journal.Pone.0059436 |
0.309 |
|
| 2013 |
Simanovsky N, Cohen-Cymberknoh M, Shoseyov D, Gileles-Hillel A, Wilschanski M, Kerem E, Hiller N. Differences in the pattern of structural abnormalities on CT scan in patients with cystic fibrosis and pancreatic sufficiency or insufficiency. Chest. 144: 208-14. PMID 23392565 DOI: 10.1378/Chest.12-1226 |
0.406 |
|
| 2013 |
Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 12: 241-8. PMID 22995323 DOI: 10.1016/J.Jcf.2012.08.016 |
0.321 |
|
| 2013 |
Cohen-Cymberknoh M, Yaakov Y, Shoseyov D, Shteyer E, Schachar E, Rivlin J, Bentur L, Picard E, Aviram M, Israeli E, Kerem E, Wilschanski M. Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis. Pediatric Pulmonology. 48: 229-35. PMID 22553157 DOI: 10.1002/Ppul.22586 |
0.404 |
|
| 2013 |
Ajayi T, Konstan M, Accurso F, De Boeck K, Kerem E, Rowe S, Sermet-Gaudelus I, Wilschanski M, Brody A, Miller N, Elfring G, Spiegel R, Peltz S, Barth J. 63 The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease Journal of Cystic Fibrosis. 12: S64. DOI: 10.1016/S1569-1993(13)60205-2 |
0.352 |
|
| 2013 |
Elborn J, Geller D, Conrad D, Aaron S, Smyth A, Fischer R, Kerem E, Bell S, Loutit J, Flume P. WS17.6 Phase 3 trial of inhaled levofloxacin (Aeroquin™, MP-376, APT-1026) vs. tobramycin inhalation solution (TIS) in intensively treated CF patients over 6 months Journal of Cystic Fibrosis. 12: S35. DOI: 10.1016/S1569-1993(13)60108-3 |
0.336 |
|
| 2013 |
Kerem E, Wilschanski M, Sermet-Gaudelus I, De Boeck K, Accurso F, Konstan M, Rowe S, Miller N, Elfring G, Spiegel R, Peltz S, Barth J, Ajayi T. WS7.5 Interim results of the phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF) Journal of Cystic Fibrosis. 12: S15. DOI: 10.1016/S1569-1993(13)60044-2 |
0.326 |
|
| 2012 |
Eisenstadt I, Calderon R, Constantini N, Nice S, Kerem E. 197 Evaluation of aerobic exercise capacity and daily functioning of patients with cystic fibrosis Journal of Cystic Fibrosis. 11: S107. DOI: 10.1016/S1569-1993(12)60367-1 |
0.314 |
|
| 2011 |
Viviani L, Assael BM, Kerem E. Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 10: 370-6. PMID 21752728 DOI: 10.1016/J.Jcf.2011.06.004 |
0.363 |
|
| 2011 |
Wilschanski M, Kerem E. New drugs for cystic fibrosis. Expert Opinion On Investigational Drugs. 20: 1285-92. PMID 21745147 DOI: 10.1517/13543784.2011.600304 |
0.384 |
|
| 2011 |
Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, ... ... Kerem E, et al. Recommendations for the classification of diseases as CFTR-related disorders. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 10: S86-102. PMID 21658649 DOI: 10.1016/S1569-1993(11)60014-3 |
0.417 |
|
| 2011 |
Kerem E, Wilschanski M, Miller NL, Pugatsch T, Cohen T, Blau H, Rivlin J, Shoseyov D, Reha A, Constantine S, Ajayi T, Hirawat S, Elfring GL, Peltz SW, Miller LL. Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 10: 193-200. PMID 21459051 DOI: 10.1016/J.Jcf.2011.02.003 |
0.347 |
|
| 2011 |
Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. American Journal of Respiratory and Critical Care Medicine. 183: 1463-71. PMID 21330455 DOI: 10.1164/Rccm.201009-1478Ci |
0.412 |
|
| 2011 |
Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, Pugatch T, Cohen-Cymberknoh M, Miller NL, Reha A, Northcutt VJ, ... ... Kerem E, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. The European Respiratory Journal. 38: 59-69. PMID 21233271 DOI: 10.1183/09031936.00120910 |
0.417 |
|
| 2011 |
Kerem E, Wilschanski M, De Boeck K, Sermet-Gaudelus I, Constantine S, Elfring G, Miller N, Barth J, Ajayi T. 65 Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data Journal of Cystic Fibrosis. 10: S17. DOI: 10.1016/S1569-1993(11)60084-2 |
0.326 |
|
| 2011 |
Cohen-Cymberknoh M, Simanovski N, Hiller N, Hillel AG, Shoseyov D, Kerem E. Comparison of disease expression between patients with primary ciliary dyskinesia (PCD) and patients with CF and pancreatic sufficiency (CF-PS) and insufficiency (CF-PI) Paediatric Respiratory Reviews. 12: S63. DOI: 10.1016/S1526-0542(11)70053-7 |
0.413 |
|
| 2010 |
Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, Malka N, Cohen L, Armoni S, Yatzkan-Israelit Y, Bergwerk A, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition. 51: 304-8. PMID 20512061 DOI: 10.1097/Mpg.0B013E3181D1B013 |
0.416 |
|
| 2010 |
Sc NN, Shoseyov D, Kerem E, Zangen DH. Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 9: 199-204. PMID 20188638 DOI: 10.1016/J.Jcf.2010.02.001 |
0.357 |
|
| 2010 |
Efrati O, Nir J, Fraser D, Cohen-Cymberknoh M, Shoseyov D, Vilozni D, Modan-Moses D, Levy R, Szeinberg A, Kerem E, Rivlin J. Meconium ileus in patients with cystic fibrosis is not a risk factor for clinical deterioration and survival: the Israeli Multicenter Study. Journal of Pediatric Gastroenterology and Nutrition. 50: 173-8. PMID 19668004 DOI: 10.1097/Mpg.0B013E3181A3Bfdd |
0.403 |
|
| 2010 |
Wilschanski M, Menachem M, Kerem E, Simanovski N, Armoni S, Kelly D, Shteyer E. Evaluation of a new ultrasound scoring system for CF liver disease Journal of Cystic Fibrosis. 9: S80. DOI: 10.1016/S1569-1993(10)60309-8 |
0.303 |
|
| 2009 |
Klein M, Cohen-Cymberknoh M, Armoni S, Shoseyov D, Chisin R, Orevi M, Freedman N, Kerem E. 18F-fluorodeoxyglucose-PET/CT imaging of lungs in patients with cystic fibrosis. Chest. 136: 1220-8. PMID 19696124 DOI: 10.1378/Chest.09-0610 |
0.335 |
|
| 2009 |
Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 8: 253-7. PMID 19447081 DOI: 10.1016/J.Jcf.2009.04.008 |
0.393 |
|
| 2009 |
Amirav I, Cohen-Cymberknoh M, Shoseyov D, Kerem E. Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis. Paediatric Respiratory Reviews. 10: 58-62. PMID 19410203 DOI: 10.1016/J.Prrv.2008.11.003 |
0.347 |
|
| 2009 |
Weintraub A, Blau H, Mussaffi H, Picard E, Bentur L, Kerem E, Stankiewicz H, Wilschanski M. Exocrine pancreatic function testing in patients with cystic fibrosis and pancreatic sufficiency: a correlation study. Journal of Pediatric Gastroenterology and Nutrition. 48: 306-10. PMID 19274786 DOI: 10.1097/Mpg.0B013E318180Af4F |
0.344 |
|
| 2009 |
Eisenstadt I, Cohen T, Kerem E. Pregnancy and CF: Differing perspectives of patients and caregivers Journal of Cystic Fibrosis. 8: S102. DOI: 10.1016/S1569-1993(09)60396-9 |
0.312 |
|
| 2008 |
Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet (London, England). 372: 719-27. PMID 18722008 DOI: 10.1016/S0140-6736(08)61168-X |
0.357 |
|
| 2008 |
Castellani C, Cuppens H, Macek M, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 7: 179-96. PMID 18456578 DOI: 10.1016/J.Jcf.2008.03.009 |
0.389 |
|
| 2008 |
Jaron R, Yaakov Y, Rivlin J, Blau H, Bentur L, Yahav Y, Kerem E, Bibi H, Picard E, Wilschanski M. Nasal potential difference in non-classic cystic fibrosis-long term follow up. Pediatric Pulmonology. 43: 545-9. PMID 18433042 DOI: 10.1002/Ppul.20807 |
0.418 |
|
| 2008 |
Segal I, Yaakov Y, Adler SN, Blau H, Broide E, Santo M, Yahav Y, Klar A, Lerner A, Aviram M, Ellis I, Mountford R, Shteyer E, Kerem E, Wilschanski M. Cystic fibrosis transmembrane conductance regulator ion channel function testing in recurrent acute pancreatitis. Journal of Clinical Gastroenterology. 42: 810-4. PMID 18360295 DOI: 10.1016/S1569-1993(07)60340-3 |
0.397 |
|
| 2008 |
Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, Bentur L, Aviram M, Rivlin J, Picard E, Lavy A, Yahav Y, Rahav G. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerging Infectious Diseases. 14: 378-84. PMID 18325250 DOI: 10.3201/Eid1403.061405 |
0.364 |
|
| 2008 |
Efrati O, Harash O, Rivlin J, Bibi H, Meir MZ, Blau H, Mussaffi H, Barak A, Levy I, Vilozni D, Kerem E, Modan-Moses D. Hemoptysis in Israeli CF patients--prevalence, treatment, and clinical characteristics. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 7: 301-6. PMID 18248858 DOI: 10.1016/J.Jcf.2007.11.007 |
0.394 |
|
| 2008 |
Schwarz M, Castellani C, Cuppens H, Macek M, Cassiman J, Kerem E, Durie P, Tullis E, Assael B, Bombieri C, Brown A, Casals T, Claustres M, Cutting G, Dodge J, et al. EUROPEAN CYSTIC FIBROSIS SOCIETY CONSENSUS ON GENETIC TESTING Journal of Cystic Fibrosis. 7: S7. DOI: 10.1016/S1569-1993(08)60496-8 |
0.304 |
|
| 2008 |
Nezer N, Shoseyov D, Kerem E, Armoni S, Zangen D. Impaired glucose metabolism in patients with CF during acute exacerbations Journal of Cystic Fibrosis. 7: S83. DOI: 10.1016/S1569-1993(08)60317-3 |
0.301 |
|
| 2008 |
Werlin S, Benuri-Silbiger I, Cohen L, Kerem E, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, Wilschanski M. Enteropathy – a new finding in cystic fibrosis Journal of Cystic Fibrosis. 7: S79. DOI: 10.1016/S1569-1993(08)60303-3 |
0.348 |
|
| 2008 |
Kerem E, Wilschanski M, Elfring G, Hirawat S, Pugatsch T, Reha A, Constantine S, Peltz S, Miller L. Quantitative cough assessment in cystic fibrosis (CF) Journal of Cystic Fibrosis. 7: S59. DOI: 10.1016/S1569-1993(08)60225-8 |
0.388 |
|
| 2008 |
Wilschanski M, Armoni S, Yaakov Y, Blau H, Shoseyov D, Cohen M, Hirawat S, Elfring G, Reha A, Miller L, Kerem E. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF Journal of Cystic Fibrosis. 7: S22. DOI: 10.1016/S1569-1993(08)60085-5 |
0.372 |
|
| 2008 |
Werlin S, Benuri-Silbiger I, Cohen L, Malka N, Kerem E, Aviram M, Bentur L, Mussaffi H, Adler SN, Bjarnasson I, Bergwerk A, Wilschanski M. 958 Enteropathy- a New Finding in Cystic Fibrosis Gastroenterology. 134: A-142. DOI: 10.1016/S0016-5085(08)60658-7 |
0.365 |
|
| 2007 |
Weiser G, Kerem E. Early intervention in CF: how to monitor the effect. Pediatric Pulmonology. 42: 1002-7. PMID 17893918 DOI: 10.1002/Ppul.20718 |
0.385 |
|
| 2007 |
Yaakov Y, Kerem E, Yahav Y, Rivlin J, Blau H, Bentur L, Aviram M, Picard E, Bdolah-Abram T, Wilschanski M. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest. 132: 1219-26. PMID 17890478 DOI: 10.1378/Chest.06-2975 |
0.379 |
|
| 2007 |
Hakim F, Kerem E, Rivlin J, Bentur L, Stankiewicz H, Bdolach-Abram T, Wilschanski M. Vitamins A and E and pulmonary exacerbations in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition. 45: 347-53. PMID 17873748 DOI: 10.1097/Mpg.0B013E31804069E5 |
0.358 |
|
| 2007 |
Vilozni D, Bentur L, Efrati O, Minuskin T, Barak A, Szeinberg A, Blau H, Picard E, Kerem E, Yahav Y, Augarten A. Spirometry in early childhood in cystic fibrosis patients. Chest. 131: 356-61. PMID 17296633 DOI: 10.1378/Chest.06-1351 |
0.405 |
|
| 2007 |
Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, Kerem B. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. The Journal of Clinical Investigation. 117: 683-92. PMID 17290305 DOI: 10.1172/Jci28523 |
0.348 |
|
| 2007 |
Wexler ID, Johannesson M, Edenborough FP, Sufian BS, Kerem E. Pregnancy and chronic progressive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 175: 300-5. PMID 17110647 DOI: 10.1164/Rccm.200605-598Oe |
0.306 |
|
| 2007 |
Kerem E, Hirawat S, Armoni S, Yaakov Y, Blau H, Rivlin J, Aviram M, Shoseyov D, Cohen M, Northcutt V, Elfring G, Miller L, Wilschanski M. 41* PTC124 activity in CF patients carrying stop mutations: results of a phase 2 study Journal of Cystic Fibrosis. 6: S10. DOI: 10.1016/S1569-1993(07)60034-4 |
0.36 |
|
| 2006 |
Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest. 130: 222-6. PMID 16840406 DOI: 10.1378/Chest.130.1.222 |
0.417 |
|
| 2006 |
Kerem E. Mutation specific therapy in CF. Paediatric Respiratory Reviews. 7: S166-9. PMID 16798551 DOI: 10.1016/J.Prrv.2006.04.213 |
0.324 |
|
| 2006 |
Kerem E. Atypical CF and CF related diseases. Paediatric Respiratory Reviews. 7: S144-6. PMID 16798544 DOI: 10.1016/J.Prrv.2006.04.219 |
0.371 |
|
| 2006 |
Efrati O, Mei-Zahav M, Rivlin J, Kerem E, Blau H, Barak A, Bujanover Y, Augarten A, Cochavi B, Yahav Y, Modan-Moses D. Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fibrosis: clinical outcome in advanced pulmonary disease. Journal of Pediatric Gastroenterology and Nutrition. 42: 222-8. PMID 16456419 DOI: 10.1097/01.Mpg.0000189348.09925.02 |
0.371 |
|
| 2006 |
Shoseyov D, Cohen B, Armoni S, Castiel Y, Wilschanski M, Kerem E. 254 Omeprazole treatment of gastro-esophageal reflux in Cystic Fibrosis. How much is enough? Journal of Cystic Fibrosis. 5: S59. DOI: 10.1016/S1569-1993(06)80231-6 |
0.343 |
|
| 2006 |
Wilschanski M, Bjarnason I, Adler S, Kerem E, Goldin E, Zimmerman J, Armom S, Yatzkan-Israelit Y, Bergwerk A. 252 First capsule endoscopy studies in Cystic Fibrosis: description of CF enteropathy Journal of Cystic Fibrosis. 5: S59. DOI: 10.1016/S1569-1993(06)80229-8 |
0.405 |
|
| 2006 |
Wilschanski M, Weintraub A, Mussaffi H, Blau H, Picard E, Bentur L, Kerem E. 241 Exocrine pancreatic function evaluation in patients with Cystic Fibrosis and pancreatic sufficiency: a correlation study Journal of Cystic Fibrosis. 5: S56. DOI: 10.1016/S1569-1993(06)80218-3 |
0.343 |
|
| 2006 |
Shoseyov D, Blum D, Armoni S, Kerem E. 159 Epidemiology of fungi in culture sputum from Cystic Fibrosis patients in Israel Journal of Cystic Fibrosis. 5: S36. DOI: 10.1016/S1569-1993(06)80143-8 |
0.359 |
|
| 2005 |
Kerem E. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Pediatric Pulmonology. 40: 183-96. PMID 15880796 DOI: 10.1002/Ppul.20200 |
0.337 |
|
| 2005 |
De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics. 115: e463-9. PMID 15772171 DOI: 10.1542/Peds.2004-1764 |
0.384 |
|
| 2005 |
Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 4: 7-26. PMID 15752677 DOI: 10.1016/J.Jcf.2004.12.002 |
0.338 |
|
| 2005 |
Barak A, Wexler ID, Efrati O, Bentur L, Augarten A, Mussaffi H, Avital A, Rivlin J, Aviram M, Yahav Y, Kerem E. Trampoline use as physiotherapy for cystic fibrosis patients. Pediatric Pulmonology. 39: 70-3. PMID 15532080 DOI: 10.1002/Ppul.20133 |
0.332 |
|
| 2004 |
Augarten A, Paret G, Avneri I, Akons H, Aviram M, Bentur L, Blau H, Efrati O, Szeinberg A, Barak A, Kerem E, Yahav J. Systemic inflammatory mediators and cystic fibrosis genotype. Clinical and Experimental Medicine. 4: 99-102. PMID 15672947 DOI: 10.1007/S10238-004-0044-1 |
0.386 |
|
| 2004 |
Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Current Opinion in Pulmonary Medicine. 10: 547-52. PMID 15510065 DOI: 10.1097/01.Mcp.0000141247.22078.46 |
0.318 |
|
| 2004 |
Picard E, Aviram M, Yahav Y, Rivlin J, Blau H, Bentur L, Avital A, Villa Y, Schwartz S, Kerem B, Kerem E. Familial concordance of phenotype and microbial variation among siblings with CF. Pediatric Pulmonology. 38: 292-7. PMID 15334505 DOI: 10.1002/Ppul.20111 |
0.382 |
|
| 2003 |
Augarten A, Berman H, Aviram M, Diver-Habber A, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Katznelson D, Szeinberg A, Kerem BS, Theodor L, Paret G, Yahav Y. Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests. Clinical and Experimental Medicine. 3: 119-23. PMID 14598187 DOI: 10.1007/S10238-003-0014-Z |
0.358 |
|
| 2003 |
Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. The New England Journal of Medicine. 349: 1433-41. PMID 14534336 DOI: 10.1056/Nejmoa022170 |
0.402 |
|
| 2003 |
Wilschanski M, Yahav J, Blau H, Bentur L, Rivlin J, Aviram M, Shushan L, Kerem B, Kerem E. Restoration of CFTR function by gentamincin in cystic fibrosis patients carrying stop mutations: a double blind placebo controlled trial Gastroenterology. 124: A582. DOI: 10.1016/S0016-5085(03)82949-9 |
0.369 |
|
| 2001 |
Goitein O, Elstein D, Abrahamov A, Hadas-Halpern I, Melzer E, Kerem E, Zimran A. Lung involvement and enzyme replacement therapy in Gaucher's disease. Qjm : Monthly Journal of the Association of Physicians. 94: 407-15. PMID 11493717 DOI: 10.1093/Qjmed/94.8.407 |
0.357 |
|
| 2001 |
Wilschanski M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, Klar A, Ilani A, Kerem B, Kerem E. Nasal potential difference measurements in patients with atypical cystic fibrosis. The European Respiratory Journal. 17: 1208-15. PMID 11491166 DOI: 10.1183/09031936.01.00092501 |
0.426 |
|
| 2001 |
Kerem E. Treatment of the hospitalized cystic fibrosis patient. Edited by David M. Orenstein and Robert C. Stern. Armonk, NY, Marcel Dekker, Inc., 1998, 446 pp. Pediatric Pulmonology. 31: 484-484. DOI: 10.1002/Ppul.1080 |
0.314 |
|
| 2000 |
Augarten A, Shmilovich H, Doolman R, Aviram M, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Sela BA, Szeinberg A, Yahav Y. Serum lipase levels as a diagnostic marker in cystic fibrosis patients with normal or borderline sweat tests. Pediatric Pulmonology. 30: 320-3. PMID 11015133 DOI: 10.1002/1099-0496(200010)30:4<320::Aid-Ppul8>3.0.Co;2-E |
0.36 |
|
| 2000 |
Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. American Journal of Respiratory and Critical Care Medicine. 161: 860-5. PMID 10712334 DOI: 10.1164/Ajrccm.161.3.9904116 |
0.402 |
|
| 1999 |
Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, MacLaughlin E, Barker P, Nash M, Quittell L, Boucher R, Knowles MR. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. The New England Journal of Medicine. 341: 156-62. PMID 10403853 DOI: 10.1056/Nejm199907153410304 |
0.337 |
|
| 1999 |
Chiba-Falek O, Parad RB, Kerem E, Kerem B. Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation. American Journal of Respiratory and Critical Care Medicine. 159: 1998-2002. PMID 10351951 DOI: 10.1164/Ajrccm.159.6.9808012 |
0.374 |
|
| 1999 |
Wilschanski M, Fisher D, Hadas-Halperin I, Picard E, Faber J, Goldberg S, Branski D, Kerem E. Findings on routine abdominal ultrasonography in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition. 28: 182-5. PMID 9932852 DOI: 10.1097/00005176-199902000-00017 |
0.385 |
|
| 1999 |
Wilschanski M, Rivlin J, Cohen S, Augarten A, Blau H, Aviram M, Bentur L, Springer C, Vila Y, Branski D, Kerem B, Kerem E. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics. 103: 52-7. PMID 9917439 DOI: 10.1542/Peds.103.1.52 |
0.384 |
|
| 1998 |
Chiba-Falek O, Kerem E, Shoshani T, Aviram M, Augarten A, Bentur L, Tal A, Tullis E, Rahat A, Kerem B. The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation. Genomics. 53: 276-83. PMID 9799593 DOI: 10.1006/Geno.1998.5517 |
0.39 |
|
| 1998 |
Chiba-Falek O, Nissim-Rafinia M, Argaman Z, Genem A, Moran I, Kerem E, Kerem B. Screening of CFTR mutations in an isolated population: Identification of carriers and patients European Journal of Human Genetics. 6: 181-184. PMID 9781064 DOI: 10.1038/Sj.Ejhg.5200174 |
0.35 |
|
| 1998 |
Rivlin J, Lerner A, Augarten A, Wilschanski M, Kerem E, Ephros MA. Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis Journal of Pediatrics. 132: 177-179. PMID 9470027 DOI: 10.1016/S0022-3476(98)70511-6 |
0.405 |
|
| 1997 |
Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: Frequency and mutation distribution Genetic Testing. 1: 35-39. PMID 10464623 DOI: 10.1089/Gte.1997.1.35 |
0.361 |
|
| 1997 |
Kerem E. The Role of Pseudomonas aeruginosa in the pathogenesis of lung disease in cystic fibrosis: More questions than answers Pediatric Pulmonology. 24: 265-266. PMID 9443305 DOI: 10.1002/Ppul.19502308137 |
0.353 |
|
| 1997 |
Kerem E, Nissim-Rafinia M, Argaman Z, Augarten A, Bentur L, Klar A, Yahav Y, Szeinberg A, Hiba O, Branski D, Corey M, Kerem B. A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype. Pediatrics. 100: E5. PMID 9271620 DOI: 10.1542/Peds.100.3.E5 |
0.355 |
|
| 1997 |
Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba-Falek O, Kraemer MR, Simon A, Branski D, et al. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. American Journal of Respiratory and Critical Care Medicine. 155: 1914-20. PMID 9196095 DOI: 10.1164/Ajrccm.155.6.9196095 |
0.43 |
|
| 1996 |
Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis Pediatric Pulmonology. 22: 387-395. PMID 9016472 DOI: 10.1002/(Sici)1099-0496(199612)22:6<387::Aid-Ppul7>3.0.Co;2-G |
0.335 |
|
| 1996 |
Kerem E, Elstein D, Abrahamov A, Bar Ziv Y, Hadas-Halpern I, Melzer E, Cahan C, Branski D, Zimran A. Pulmonary function abnormalities in type I Gaucher disease European Respiratory Journal. 9: 340-345. PMID 8777974 DOI: 10.1183/09031936.96.09020340 |
0.382 |
|
| 1996 |
Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. European Journal of Human Genetics : Ejhg. 4: 65-73. PMID 8744024 DOI: 10.1159/000472174 |
0.379 |
|
| 1995 |
Kerem E, Kerem B. The relationship between genotype and phenotype in cystic fibrosis Current Opinion in Pulmonary Medicine. 1: 450-456. PMID 9363081 DOI: 10.1097/00063198-199511000-00004 |
0.33 |
|
| 1995 |
Augarten A, Hacham S, Kerem E, Sheva Kerem B, Szeinberg A, Laufer J, Doolman R, Altshuler R, Blau H, Bentur L. The significance of sweat Cl/Na ratio in patients with borderline sweat test. Pediatric Pulmonology. 20: 369-71. PMID 8649916 DOI: 10.1002/Ppul.1950200606 |
0.383 |
|
| 1995 |
Kerem E, Kalman YM, Yahav Y, Shoshani T, Abeliovich D, Szeinberg A, Rivlin J, Blau H, Tal A, Ben-Tur L, Springer C, Augarten A, Godfrey S, Lerer I, Branski D, et al. Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel Human Genetics. 96: 193-197. PMID 7635469 DOI: 10.1007/Bf00207378 |
0.347 |
|
| 1994 |
Kerem E, Diav O, Navon P, Branski D. Pleural fluid characteristics in pulmonary brucellosis Thorax. 49: 89-90. PMID 8153949 DOI: 10.1136/Thx.49.1.89 |
0.303 |
|
| 1994 |
Kerem E, Ziv YB, Rudenski B, Katz S, Kleid D, Branski D. Bacteremic necrotizing pneumococcal pneumonia in children American Journal of Respiratory and Critical Care Medicine. 149: 242-244. PMID 8111589 DOI: 10.1164/Ajrccm.149.1.8111589 |
0.352 |
|
| 1994 |
Kalman YM, Kerem E, Darvasi A, DeMarchi J, Kerem B. Difference in frequencies of the cystic fibrosis alleles, ΔF508 and W1282X, between carriers and patients European Journal of Human Genetics. 2: 77-82. PMID 8044659 DOI: 10.1159/000472347 |
0.349 |
|
| 1994 |
Shoshani T, Kerem E, Szeinberg A, Augarten A, Yahav Y, Cohen D, Rivlin J, Tal A, Kerem BS. Similar levels of mRNA from the W1282X and the ΔF508 cystic fibrosis alleles, in nasal epithelial cells Journal of Clinical Investigation. 93: 1502-1507. PMID 7512981 DOI: 10.1172/Jci117128 |
0.39 |
|
| 1993 |
Kerem E, Elpelg ON, Shalev RS, Rosenman E, Bar Ziv Y, Branski D. Lysinuric protein intolerance with chronic interstitial lung disease and pulmonary cholesterol granulomas at onset. The Journal of Pediatrics. 123: 275-8. PMID 8345427 DOI: 10.1016/S0022-3476(05)81703-2 |
0.317 |
|
| 1993 |
Augarten A, Yahav Y, Szeinberg A, Noiman S, Gazit E, Kerem BS, Rivlin Y, Tal A, Blau H, Ben-Tur L, Kerem E. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C → T mutation The Lancet. 342: 25-26. PMID 8100293 DOI: 10.1016/0140-6736(93)91885-P |
0.419 |
|
| 1993 |
Shoshani T, Berkun Y, Yahav Y, Augarten A, Bashan N, Rivlin Y, Gazit E, Sereth H, Kerem E, Kerem BS. A new mutation in the CFTR gene, composed of two adjacent DNA alterations, is a common cause of cystic fibrosis among Georgian Jews Genomics. 15: 236-237. PMID 7679367 DOI: 10.1006/Geno.1993.1046 |
0.34 |
|
| 1992 |
Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. The New England Journal of Medicine. 326: 1187-91. PMID 1285737 DOI: 10.1056/Nejm199204303261804 |
0.347 |
|
| 1991 |
Blayney M, Kerem E, Whyte H, O'Brodovich H. Bronchopulmonary dysplasia: Improvement in lung function between 7 and 10 years of age The Journal of Pediatrics. 118: 201-206. PMID 1993945 DOI: 10.1016/S0022-3476(05)80483-4 |
0.307 |
|
| 1990 |
Kerem E, Bentur L, England S, Reisman J, O'Brodovich H, Bryan AC, Levison H. Sequential pulmonary function measurements during treatment of infantile chronic interstitial pneumonitis. The Journal of Pediatrics. 116: 61-7. PMID 2295964 DOI: 10.1016/S0022-3476(05)81646-4 |
0.331 |
|
| 1990 |
Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). The New England Journal of Medicine. 323: 1517-22. PMID 2233932 DOI: 10.1056/Nejm199011293232203 |
0.424 |
|
| 1990 |
Kerem E, Corey M, Stein R, Gold R, Levison H. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients. The Pediatric Infectious Disease Journal. 9: 494-8. PMID 2115157 DOI: 10.1097/00006454-199007000-00008 |
0.343 |
|
| 1990 |
Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. The Journal of Pediatrics. 116: 714-9. PMID 2109790 DOI: 10.1016/S0022-3476(05)82653-8 |
0.364 |
|
| 1990 |
Bentur L, Kerem E, Couper R, Baumal R, Canny G, Durie P, Levison H. Renal calcium handling in cystic fibrosis: lack of evidence for a primary renal defect. The Journal of Pediatrics. 116: 556-60. PMID 1690795 DOI: 10.1016/S0022-3476(05)81602-6 |
0.355 |
|
| 1990 |
Durie P, Tsui L, Corey M, Kerem E, Kerem B, Romunens J, Levison H. GASTROINTESTINAL MANIFESTATIONS OF CF PATIENTS CARRYING THE Δ F5O8 MUTATION Pediatric Research. 27: 542-542. DOI: 10.1203/00006450-199005000-00101 |
0.304 |
|
| Show low-probability matches. |